Scott L. Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 7,500 shares at $87.55 ($658K) on 2026-07-01, disclosed to the SEC on 2026-07-02.
Scheduled sale ($658k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $87.55 | 5,775 | $506K | 76.8% |
| 2 | $88.37 | 1,725 | $152K | 23.2% |
| Total | $87.74 avg | 7,500 | $658K | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $717K | — | Filing → |
| SYRE | SELL | 2026-06-26 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $533K | — | Filing → |